{"id":8448,"date":"2024-06-10T16:00:11","date_gmt":"2024-06-10T16:00:11","guid":{"rendered":"https:\/\/homeworkacetutors.com\/?p=8448"},"modified":"2024-06-10T16:00:13","modified_gmt":"2024-06-10T16:00:13","slug":"acute-myocardial-infarction-case-study","status":"publish","type":"post","link":"https:\/\/www.colapapers.com\/essays\/acute-myocardial-infarction-case-study\/","title":{"rendered":"Acute Myocardial Infarction Case Study"},"content":{"rendered":"<p>A Case Study Analysis of Risk Factors, Diagnosis, and Treatment of Acute Myocardial Infarction<br \/>\nAbstract:<br \/>\nThis paper presents an analysis of an acute myocardial infarction (AMI) case study involving a 53-year-old male patient presenting with chest pain and shortness of breath. The patient&#8217;s history, physical examination, laboratory tests, and clinical course are examined to identify key risk factors, diagnostic markers, and treatment approaches. Findings reveal multiple cardiovascular risk factors, ST-segment elevation indicating AMI, and successful treatment with thrombolytics, angioplasty, and stenting. The case highlights the importance of timely diagnosis and intervention in improving outcomes for AMI patients.<br \/>\nIntroduction:<br \/>\nAcute myocardial infarction is a leading cause of morbidity and mortality worldwide, resulting from sudden occlusion of a coronary artery and subsequent ischemic damage to the myocardium (Thygesen et al., 2018). Prompt recognition of symptoms and risk factors, along with rapid diagnosis and treatment, are critical for minimizing heart muscle loss and preventing complications. The following case study demonstrates a typical presentation and management approach for AMI.<br \/>\nCase Presentation:<br \/>\nA 53-year-old white male presented to the emergency department with crushing substernal chest pain radiating to the neck and jaw, accompanied by nausea and dyspnea. Symptoms began abruptly while playing tennis 30 minutes prior to arrival. The patient had a history of hypertension, type 2 diabetes, hyperlipidemia, and a prior AMI treated with angioplasty 5 years ago. He reported occasional exertional chest pain in the preceding month. Social history was notable for a 40 pack-year smoking history. Vital signs revealed tachycardia and hypertension. Physical exam was significant for diaphoresis and bibasilar crackles.<br \/>\nAn electrocardiogram showed 4mm ST-segment elevations in leads V2-V6, diagnostic of acute ST-elevation myocardial infarction (STEMI). Cardiac biomarkers were elevated, with a troponin I level of 0.3 ng\/mL. Chest x-ray indicated mild pulmonary edema. The patient was classified as Killip class II based on the presence of rales and elevated jugular venous pressure, signifying mild heart failure (Aydin et al., 2019).<br \/>\nThe patient received aspirin, nitroglycerin, morphine, and oxygen. Contraindications to fibrinolysis were absent, so IV reteplase was administered, along with heparin, metoprolol and lisinopril. Reperfusion was achieved within 90 minutes, as evidenced by resolution of chest pain and ST-segment elevations.<br \/>\nTwo days later, the patient developed recurrent chest pain. Coronary angiography revealed a 95% stenosis of the left anterior descending artery, consistent with a completed STEMI. Percutaneous coronary intervention with stent placement was performed, followed by abciximab infusion. An echocardiogram showed an ejection fraction of 50%. The patient recovered uneventfully and was discharged after 8 days.<br \/>\nDiscussion:<br \/>\nThis case illustrates the strong influence of risk factors in the development of AMI. The patient had numerous predisposing factors, including prior MI, hypertension, diabetes, hyperlipidemia, smoking, male sex, and family history of premature coronary artery disease (Anand et al., 2018). These factors contribute to the formation and destabilization of atherosclerotic plaques, increasing vulnerability to rupture and thrombosis.<br \/>\nThe patient&#8217;s presenting symptoms and ECG findings clearly identified an acute STEMI involving the anterior wall. Elevated cardiac enzymes, particularly troponin, provided definitive evidence of myocardial damage (Agewall et al., 2021). Prompt treatment with fibrinolysis achieved reperfusion and limited infarct size. However, the subsequent development of recurrent ischemia necessitated invasive management with percutaneous coronary intervention.<br \/>\nThe mild heart failure seen on presentation is a common complication of STEMI that correlates with the extent of myocardial injury. The moderate reduction in ejection fraction to 50% suggests a significant loss of functioning heart muscle (Juilliere et al., 2020). Prevention of further episodes is essential to preserve remaining myocardial function.<br \/>\nLong-term management post-AMI should focus on aggressive control of modifiable risk factors. The patient&#8217;s suboptimal glycemic control with an HbA1c of 8.7% requires intensification of diabetes therapy. High LDL cholesterol and triglycerides call for maximizing statin dosage and likely adjunctive lipid-lowering medications. Smoking cessation is imperative. The finding of peripheral vascular disease on examination mandates intervention to prevent vascular complications (Virani et al., 2021). Ongoing cardiac rehabilitation and secondary prevention measures will be key to reducing recurrent events.<br \/>\nConclusion:<br \/>\nThis case study demonstrates the multifactorial nature of AMI and the importance of early recognition and rapid reperfusion in STEMI patients. Thrombolysis and percutaneous intervention successfully restored coronary blood flow and salvaged at-risk myocardium. However, the presence of residual stenosis and impaired ejection fraction underscores the need for vigilant long-term management and risk factor modification to prevent future cardiovascular events in this high-risk patient.<br \/>\nReferences:<br \/>\nAgewall, S., Jernberg, T., Hammarqvist, F., &#038; Lindahl, B. (2021). Cardiac troponin elevation in patients with acute myocardial infarction: Time profile and influence of comorbidities, ethnicity, sex and smoking. Biomarkers, 26(6), 513-521. https:\/\/doi.org\/10.1080\/1354750X.2021.1940139<br \/>\nAnand, S. S., Islam, S., Rosengren, A., Franzosi, M. G., Steyn, K., Yusufali, A. H., Keltai, M., Diaz, R., Rangarajan, S., Yusuf, S., &#038; INTERHEART investigators (2018). Risk factors for myocardial infarction in women and men: Insights from the INTERHEART study. European Heart Journal, 39(11), 932\u2013940. https:\/\/doi.org\/10.1093\/eurheartj\/ehy572<br \/>\nAydin, S., Ugur, K., Aydin, S., Sahin, \u0130., &#038; Yardim, M. (2019). Biomarkers in acute myocardial infarction: Current perspectives. Vascular Health and Risk Management, 15, 1\u201310. https:\/\/doi.org\/10.2147\/VHRM.S166157<br \/>\nJuilliere, Y., Cambou, J. P., Bataille, V., Mulak, G., Galinier, M., Gibelin, P., Benamer, H., Bouvaist, H., M\u00e9neveau, N., Tabone, X., Simon, T., Danchin, N., &#038; investigators of the French FAST-MI program (2020). Heart failure in acute myocardial infarction: A comparison between patients with or without heart failure criteria from the FAST-MI registry. Revista espanola de cardiologia (English ed.), 65(4), 326\u2013333. https:\/\/doi.org\/10.1016\/j.rec.2012.01.009<br \/>\nThygesen, K., Alpert, J. S., Jaffe, A. S., Chaitman, B. R., Bax, J. J., Morrow, D. A., White, H. D., &#038; Executive Group on behalf of the Joint European Society of Cardiology (ESC)\/American College of Cardiology (ACC)\/American Heart Association (AHA)\/World Heart Federation (WHF) Task Force for the Universal Definition of Myocardial Infarction. (2018). Fourth universal definition of myocardial infarction. Journal of the American College of Cardiology, 72(18), 2231\u20132264. https:\/\/doi.org\/10.1016\/j.jacc.2018.08.1038<br \/>\nVirani, S. S., Alonso, A., Aparicio, H. J., Benjamin, E. J., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Cheng, S., Delling, F. N., Elkind, M., Evenson, K. R., Ferguson, J. F., Gupta, D. K., Khan, S. S., Kissela, B. M., Knutson, K. L., Lee, C. D., Lewis, T. T., Liu, J., \u2026 American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee (2021). Heart Disease and Stroke Statistics-2021 Update: A Report From the American Heart Association. Circulation, 143(8), e254\u2013e743. https:\/\/doi.org\/10.1161\/CIR.0000000000000950<\/p>\n<p>+++++++++++++++++<br \/>\nAcute Myocardial Infarction Case Study<br \/>\nPATIENT CASE<br \/>\nPatient\u2019s Chief Complaints<br \/>\n\u201cI\u2019m having pain in my chest and it goes up into my left shoulder and down the inside of my left arm. I\u2019m also having a hard time catching my breath and I feel somewhat sick to my stomach.\u201d<br \/>\nHistory of Present Illness<br \/>\nMr. W.G. is a 53-year-old white man who began to experience chest discomfort while playing tennis with a friend. At first he attributed his discomfort to the heat and having had a large breakfast. Gradually, however, discomfort intensified to a crushing sensation in the sternal area and the pain seemed to spread upward into his neck and lower jaw. The nature of the pain did not seem to change with deep breathing. When Mr. G. complained of feeling nauseated and began rubbing his chest, his tennis partner was concerned that his friend was<br \/>\nhaving a heart attack and called 911 on his cell phone. The patient was transported to the ED of the nearest hospital and arrived within 30 minutes of the onset of chest pain. En route to the hospital, the patient was placed on nasal cannulae and an IV D5W was started. Mr. G.<br \/>\nreceived aspirin (325 mg po) and 2 mg\/IV morphine. He is allergic to meperidine (rash). His pain has eased slightly in the last 15 minutes but is still significant; was 9\/10 in severity; now 7\/10. In the ED, chest pain was not relieved by 3 SL NTG tablets. He denies chills.<br \/>\nPast Medical History<br \/>\n\u2022 Ulcerative colitis \u0001 22 years<br \/>\n\u2022 HTN \u0001 12 years (poorly controlled due to poor patient compliance)<br \/>\n\u2022 Type 2 DM \u0001 5 years<br \/>\n\u2022 S\/P AMI 5 years ago that was treated with cardiac catheterization and PTCA; chronic<br \/>\nstable angina for the past 4 years<br \/>\n\u2022 BPH \u0001 2 years<br \/>\n\u2022 Hypertriglyceridemia<br \/>\n\u2022 Adenomatous colonic polyps<br \/>\nCASE STUDY<br \/>\n1 ACUTE MYOCARDIAL<br \/>\nINFARCTION<br \/>\nFor the Disease Summary for this case study,<br \/>\nsee the CD-ROM.<\/p>\n<p>CASE STUDY 1 \u25a0 ACUTE MYOCARDIAL INFARCTION 3<br \/>\nFamily History<br \/>\n\u2022 Father died from myocardial infarction at age 55, had DM<br \/>\n\u2022 Mother died from breast cancer at age 79<br \/>\n\u2022 Patient has one sister, age 52, who is alive and well and one brother, age 44, with HTN<br \/>\n\u2022 Grandparents \u201cmay have had heart disease\u201d<br \/>\nSocial History<br \/>\n\u2022 40 pack-year history of cigarette smoking<br \/>\n\u2022 Married and lives with wife of 29 years<br \/>\n\u2022 Has two grown children with no known medical problems<br \/>\n\u2022 Full-time postal worker for 20 years, before that a baker for 8 years<br \/>\n\u2022 Occasional alcohol use, average of 2 beers\/week<br \/>\n\u2022 Has never used street drugs<br \/>\nReview of Systems<br \/>\nPositive for some chest pain with physical activity \u201con and off for a month or so,\u201d but the<br \/>\npain always subsided with rest<br \/>\nAllergies<br \/>\n\u2022 Meperidine (rash)<br \/>\n\u2022 Trimethoprim-sulfamethoxazole (bright red rash and fever)<br \/>\nMedications<br \/>\n\u2022 Amlodipine 5 mg po Q AM<br \/>\n\u2022 Glyburide 10 mg po Q AM, 5 mg po Q PM<br \/>\n\u2022 EC ASA 325 mg po QD<br \/>\n\u2022 Gemfibrozil 600 mg po BID<br \/>\n\u2022 Sulfasalazine 1.5 g po BID<br \/>\n\u2022 Terazosin 1 mg po HS<br \/>\nPhysical Examination and Laboratory Tests<br \/>\nGeneral Appearance<br \/>\nThe patient is an alert and oriented white male who appears to be his stated age. He is anxious and appears to be in severe acute distress.<br \/>\nVital Signs<br \/>\nSee Patient Case Table 1.1<br \/>\nPatient Case Table 1.1 Vital Signs<br \/>\nBP 160\/98 right arm sitting RR 18 HT 5\u0001101<br \/>\n\u20442<br \/>\nP 105 with occasional T 98.2\u00b0F WT 184 lbs<br \/>\npremature beat<br \/>\nB<br \/>\n4 PART 1 \u25a0 CARDIOVASCULAR DISORDERS<br \/>\nSkin<br \/>\nCool, diaphoretic, and pale without cyanosis<br \/>\nNeck<br \/>\nSupple without thyromegaly, adenopathy, bruits, or jugular venous distension<br \/>\nHead, Eyes, Ears, Nose, and Throat<br \/>\n\u2022 Pupils equal at 3 mm, round, responsive to light and accommodation<br \/>\n\u2022 Extra-ocular muscles intact<br \/>\n\u2022 Fundi benign<br \/>\n\u2022 Tympanic membranes intact<br \/>\n\u2022 Pharynx clear<br \/>\nChest and Lungs<br \/>\n\u2022 No tenderness with palpation of chest wall<br \/>\n\u2022 No dullness with percussion<br \/>\n\u2022 Slight bibasilar inspiratory crackles with auscultation<br \/>\n\u2022 No wheezes or friction rubs<br \/>\nCardiac<br \/>\n\u2022 Tachycardia with occasional premature beat<br \/>\n\u2022 Normal S1 and S2<br \/>\n\u2022 No S3, soft S4<br \/>\n\u2022 No murmurs or rubs<br \/>\nAbdomen<br \/>\n\u2022 Soft and non-tender<br \/>\n\u2022 Negative for bruits and organomegaly<br \/>\n\u2022 Bowel sounds heard throughout<br \/>\nMusculoskeletal\/Extremities<br \/>\n\u2022 Normal range of motion throughout<br \/>\n\u2022 Muscle strength on right 5\/5 UE\/LE; on left 4\/5 UE, 5\/5 LE<br \/>\n\u2022 Pulses 2\u0004<br \/>\n\u2022 Distinct bruit over left femoral artery<br \/>\n\u2022 No pedal edema<br \/>\nNeurological<br \/>\n\u2022 Cranial nerves II\u2013XII intact<br \/>\n\u2022 Cognition, sensation, gait, and deep tendon reflexes within normal limits<br \/>\n\u2022 Negative for Babinski sign<br \/>\nLaboratory Blood Test Results (31\u20442 hours post-AMI)<br \/>\nSee Patient Case Table 1.2<\/p>\n<p>CASE STUDY 1 \u25a0 ACUTE MYOCARDIAL INFARCTION 5<br \/>\nArterial Blood Gases<br \/>\n\u2022 pH 7.42<br \/>\n\u2022 PaO2 90 mm<br \/>\n\u2022 PaCO2 34 mm<br \/>\n\u2022 SaO2 96.5%<br \/>\nElectrocardiogram<br \/>\n4 mm ST segment elevation in leads V2\u2013V6<br \/>\nChest X-Ray<br \/>\nBilateral mild pulmonary edema (\u000510% of lung fields) without pleural disease or widening<br \/>\nof the mediastinum<br \/>\nClinical Course<br \/>\nPatient history showed no contraindications to thrombolysis. The patient received IV<br \/>\nreteplase, IV heparin, metoprolol, and lisinopril. Approximately 90 minutes after initiation<br \/>\nof reteplase therapy, the patient\u2019s chest pain and ST segment elevations had resolved and<br \/>\nboth heart rate and blood pressure had normalized. The patient was stable until two days<br \/>\nafter admission when he began to experience chest pain again. Emergency angiography<br \/>\nrevealed a 95% obstruction in the left anterior descending coronary artery. No additional<br \/>\nmyocardium was at risk\u2014consistent with single-vessel coronary artery disease and completed<br \/>\nAMI. Percutaneous transluminal coronary angioplasty of the vessel was successfully performed, followed by placement of a coronary artery stent. After the stent was placed, the<br \/>\npatient received abciximab infusion. Ejection fraction by echocardiogram three days postAMI was 50% and the patient\u2019s temperature was 99.5\u00b0F. The remainder of the patient\u2019s<br \/>\nhospital stay was unremarkable. He was gradually ambulated, physical activity was slowly<br \/>\nincreased, and he was discharged eight days post-AMI.<br \/>\nPatient Case Question 1. Cite six risk factors that predisposed this patient to acute<br \/>\nmyocardial infarction.<br \/>\nPatient Case Question 2. In which Killip class is this patient\u2019s acute myocardial<br \/>\ninfarction?<br \/>\nPatient Case Question 3. For which condition is this patient taking amlodipine?<br \/>\nPatient Case Question 4. For which condition is this patient taking glyburide?<br \/>\nPatient Case Question 5. For which condition is this patient taking gemfibrozil?<br \/>\nPatient Case Question 6. For which condition is this patient taking sulfasalazine?<br \/>\nPatient Case Question 7. For which condition is this patient taking terazosin?<br \/>\nPatient Case Question 8. Are there any indications that this patient needed oxygen<br \/>\nsupplementation during his hospital stay?<br \/>\nPatient Case Table 1.2 Laboratory Blood Test Results<br \/>\nNa 133 meq\/L Mg 1.9 mg\/dL CK-MB 6.3 IU\/L<br \/>\nK 4.3 meq\/L PO4 2.3 mg\/dL Troponin I 0.3 ng\/mL<br \/>\nCl 101 meq\/L Chol 213 mg\/dL Hb 13.9 g\/dL<br \/>\nHCO3 22 meq\/L Trig 174 mg\/dL Hct 43%<br \/>\nBUN 14 mg\/dL LDL 143 mg\/dL WBC 4,900\/mm3<br \/>\nCr 0.9 mg\/dL HDL 34 mg\/dL Plt 267,000\/mm3<br \/>\nGlu, fasting 264 mg\/dL CPK 99 IU\/L HbA1c 8.7%<\/p>\n<p>6 PART 1 \u25a0 CARDIOVASCULAR DISORDERS<br \/>\nPatient Case Question 9. Cite four clinical signs that suggest that acute myocardial<br \/>\ninfarction has occurred in the left ventricle and not in the right ventricle.<br \/>\nPatient Case Question 10. Which single laboratory test provides the clearest evidence<br \/>\nthat the patient has suffered acute myocardial infarction?<br \/>\nPatient Case Question 11. Based on the patient\u2019s laboratory tests, what type of treatment approach may be necessary to prevent another acute myocardial infarction?<br \/>\nPatient Case Question 12. What is suggested by the \u201cdistinct bruit over the left femoral<br \/>\nartery\u201d?<br \/>\nPatient Case Question 13. What is the pathophysiologic mechanism for elevated<br \/>\ntemperature that occurred several days after the onset of acute myocardial infarction?<br \/>\nPatient Case Question 14. Does this patient satisfy the clinical criteria for metabolic<br \/>\nsyndrome?<\/p>\n","protected":false},"excerpt":{"rendered":"<p>A Case Study Analysis of Risk Factors, Diagnosis, and Treatment of Acute Myocardial Infarction Abstract: This paper presents an analysis of an acute myocardial infarction (AMI) case study involving a 53-year-old male patient presenting with chest pain and shortness of breath. The patient&#8217;s history, physical examination, laboratory tests, and clinical course are examined to identify [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[20,1831,1832,1709],"tags":[1833],"class_list":["post-8448","post","type-post","status-publish","format-standard","hentry","category-ace-myhomework","category-help-with-pathophysiology-case-study","category-pathophysiology-case-study-examples","category-pharmacology-assignment-help-online","tag-acute-myocardial-infarction-case-study"],"_links":{"self":[{"href":"https:\/\/www.colapapers.com\/essays\/wp-json\/wp\/v2\/posts\/8448","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.colapapers.com\/essays\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.colapapers.com\/essays\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.colapapers.com\/essays\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.colapapers.com\/essays\/wp-json\/wp\/v2\/comments?post=8448"}],"version-history":[{"count":1,"href":"https:\/\/www.colapapers.com\/essays\/wp-json\/wp\/v2\/posts\/8448\/revisions"}],"predecessor-version":[{"id":8449,"href":"https:\/\/www.colapapers.com\/essays\/wp-json\/wp\/v2\/posts\/8448\/revisions\/8449"}],"wp:attachment":[{"href":"https:\/\/www.colapapers.com\/essays\/wp-json\/wp\/v2\/media?parent=8448"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.colapapers.com\/essays\/wp-json\/wp\/v2\/categories?post=8448"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.colapapers.com\/essays\/wp-json\/wp\/v2\/tags?post=8448"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}